Infectious Disease · Topic 4 of 10

Bacteremia & Staphylococcus aureus Bacteremia

Infectious disease · bloodstream infection

Bacteremia & Staphylococcus aureus Bacteremia

S. aureus in the blood: repeat cultures until clear, echo every patient, remove the source, and give a beta-lactam for MSSA for at least 14 days.

Key numbers

Repeat blood cultures until negativeq24–48 h

14 days; 4–6 weeks if deep focus≥ 14 d / 4–6 wk

Dose vancomycin to an AUC of 400–600AUC 400–600 mg·h/L

01 · DoRepeat blood cultures until negative

Draw at least 2 sets of follow-up blood cultures 48 hours after the first positive set, then every 24–48 hours until negative; the first negative culture is day 1 of the treatment course.

02 · DoTTE for all; TEE if high-risk

Order a TTE in every adult with SAB. Add TEE even after a good negative TTE for a cardiac device, valve disease or prior endocarditis, positive cultures at ≥ 48 hours, emboli, or multiple foci.

03 · The rule14 days; 4–6 weeks if deep focus

Treat SAB without a deep-seated or metastatic focus for 14 days counted from the first negative blood culture; endocarditis, osteomyelitis and other deep or metastatic foci need 4–6 weeks.

Causes & risk factors

Why it happens

Risk factors for metastatic SABKey risk factors for a deep or metastatic focus: community-onset SAB, positive cultures ≥ 48 hours after the first, and an intracardiac device; also injection drug use, valve disease, endovascular graft, SAB within 90 days.

Presentation

What you'll see

Positive at 48 h: hunt for focusBlood cultures still positive 48 hours or more after the first are the strongest predictor of a deep-seated focus: re-examine the patient, image symptomatic sites, reassess source control and obtain TEE.

Diagnosis & monitoring

Work-up

Dose vancomycin to an AUC of 400–600Dose vancomycin for MRSA bacteremia by AUC, targeting 400–600 mg·h/L, after a 20–35 mg/kg loading dose; trough-guided dosing to 15–20 mg/L works but causes more kidney injury.

Do right now

In this order

First moves

MSSA: switch to cefazolin or nafcillin

→

Remove the central line and control the source

→

Repeat blood cultures until negativeq24–48 h

→

TTE for all; TEE if high-risk

→

Consult infectious diseases for every SAB

Why each step

MSSA: switch to cefazolin or nafcillinStart vancomycin or daptomycin empirically; once susceptibilities return, switch MSSA to cefazolin or an antistaphylococcal penicillin (nafcillin, oxacillin) — beta-lactams give better outcomes than vancomycin for MSSA.

Remove the central line and control the sourceSource control is essential: remove infected intravascular catheters promptly (delays beyond 3 days raise relapse), drain abscesses, debride, and remove infected cardiac devices; early source control speeds clearance and lowers mortality.

Repeat blood cultures until negativeDraw at least 2 sets of follow-up blood cultures 48 hours after the first positive set, then every 24–48 hours until negative; the first negative culture is day 1 of the treatment course.

TTE for all; TEE if high-riskOrder a TTE in every adult with SAB. Add TEE even after a good negative TTE for a cardiac device, valve disease or prior endocarditis, positive cultures at ≥ 48 hours, emboli, or multiple foci.

Consult infectious diseases for every SABRequest infectious diseases consultation for patients with SAB; bedside ID involvement is associated with lower mortality and more complete work-up (follow-up cultures, echocardiography, adequate duration).

Management

Orders

Daptomycin for MRSA — never for pneumoniaDaptomycin is the main alternative to vancomycin for MRSA bacteremia (FDA dose 6 mg/kg daily; many use 8–10 mg/kg) but is not reliably active in the lung — never use it for MRSA pneumonia.

Red flags & don'ts

Avoid harm

One-third develop metastatic infection complicationSAB seeds metastatic infection in over one-third of patients — endocarditis (about 12%), septic arthritis, vertebral osteomyelitis, epidural, psoas or splenic abscess — so new back, joint or abdominal pain needs targeted imaging.

Do not add gentamicin or rifampin routinely avoidRoutine combination therapy (adding gentamicin or rifampin to the backbone agent) has not improved outcomes in SAB, and low-dose gentamicin increases kidney injury.

The rules

Know these

Other bacteremia: 7 days is usually enoughFor bloodstream infection from other organisms (mostly gram-negatives from urinary, abdominal or lung sources) without a focus needing longer therapy, 7 days of antibiotics was noninferior to 14 days; S. aureus was excluded.

MSSA or MRSA bacteremia?

Commonly confused

Empiric therapy	Vancomycin or daptomycin until susceptibilities return
Definitive therapy	Cefazolin, nafcillin or oxacillin
Avoid	Staying on vancomycin — worse outcomes than a beta-lactam
Duration	14 days without a deep focus; 4–6 weeks with one

Commonly confused

Tell apart

Single coagulase-negative staph culture: confirm firstA single positive blood culture growing coagulase-negative staphylococci may be contamination; repeat paired cultures before starting antibiotics or pulling the catheter, because coagulase-negative staphylococci are true pathogens mainly with lines or hardware.

More detail

Reference

Show 6 reference facts

Low-risk SAB can be switched to oral antibiotics after 5–7 days of IV therapy (SABATO trial, noninferior); patients with complicated bacteremia were excluded, so step-down belongs with ID input.

In complicated SAB after blood culture clearance (left-sided endocarditis excluded), dalbavancin 1500 mg IV on days 1 and 8 was noninferior in clinical efficacy to 4–8 weeks of standard IV therapy (DOTS trial).

Cefazolin was associated with lower 30-day mortality and less nephrotoxicity than antistaphylococcal penicillins in MSSA bacteremia; ceftobiprole (FDA-approved for SAB in 2024) was noninferior to daptomycin.

S. aureus is the leading cause of death from bacteremia worldwide, with 30-day case fatality of 15–30%; bacteremia lasting 48 hours or more carries about 39% 90-day mortality.

In increased-risk SAB with no focus found after cultures, echocardiography and symptom-directed imaging, whole-body FDG-PET/CT or targeted CT and venous duplex imaging can uncover occult foci.

SAB is especially common with intravascular catheters and other foreign bodies, hemodialysis access, recent surgery, injection drug use and diabetes, but can occur with no obvious primary site.

Pearl

Culture, echo, source, consult: clear the blood, look at the valves, pull the line, and call ID.

Sources · IDSA/ESCMID 2026 Consensus Statements on Staphylococcus aureus Bacteremia: Risk Stratification, Diagnostic Evaluation, and Management (published Sept 9, 2026) · Tong SYC, Fowler VG Jr, Skalla L, Holland TL. Management of Staphylococcus aureus Bacteremia: A Review. JAMA 2025 · Merck Manual Professional — Staphylococcal Infections · Liu C et al. Clinical Practice Guidelines by the IDSA for the Treatment of MRSA Infections in Adults and Children. Clin Infect Dis 2011;52:e18–e55 · Mermel LA et al. Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the IDSA. Clin Infect Dis 2009;49:1–45 · Merck Manual Professional — Bacteremia · BALANCE Investigators. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N Engl J Med 2025 (abstract via Europe PMC) · Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial. JAMA 2025 · Rybak MJ et al. Therapeutic monitoring of vancomycin for serious MRSA infections: revised consensus guideline (ASHP/IDSA/PIDS/SIDP). Am J Health Syst Pharm 2020;77:835–864 (open copy at ashp.org) · Starter sheet built from the verified AGACNP fact map (facts reviewed 2026-10-15).